Metastatic prostate cancer is currently associated with high morbidity and mortality rates. In addition, patients respond very differently to standard treatments such as hormone therapy or radiation ...

A powerful new drug combo has yielded a major breakthrough for men battling an aggressive form of prostate cancer, researchers found in a clinical trial. File Photo by Brian Kersey/UPI A powerful new ...

In prostate cancer, prostate brachytherapy boost improves biochemical failure at 10 years but does not prolong long-term OS compared to EBRT boost.

Prostate cancer is the most common cancer in American men, with an estimated 333,830 new cases and 36,320 deaths projected for 2026 for the disease, according to the American Cancer ...

A new drug combination may benefit men whose prostate cancer has returned after primary surgery or radiation therapy. Pairing enzalutamide, an androgen receptor blocker, with the hormone therapy drug ...

Scientists have reported results from an early-stage trial of an immunotherapy drug called VIR-5500. The drug offers new hope for men with advanced prostate cancer who have stopped responding to other ...

Long-term results from a European study showed that prostate cancer mortality was 13% lower in the PSA screening group versus the control group. Compared with the trial update at 16 years, the number ...

The latest American Cancer Society report shows a 34% drop in cancer mortality since 1991, but reveals a worrying increase in ...

People who have received a cancer diagnosis are living longer than ever, according to a new report from the American Cancer Society (ACS). Decades of cancer research have led to more effective ...

MyMichigan Medical Center Sault has begun offering PSMA PET scans, providing men in the eastern Upper Peninsula with an advanced imaging tool to detect prostate cancer.